Five9 Shorts Pile In Ahead of Q3 Print

FIVN heads into its November 5 earnings report with short interest running at its highest level in months and retail attention surging, even as the stock itself has held up better than bears might have hoped.

The most striking development this week is the jump in short positioning. Short interest has climbed to 14.2% of the free float, up 8.1% in a week and 32.8% over the past month. The bulk of that move appeared in a single day: shares short jumped from roughly 9.4 million to 11.1 million between October 23 and October 27, a sharp acceleration into the earnings window. Despite that build, the lending market is not flashing stress. Availability is ample at 775%, meaning there are around seven shares available to borrow for every one already lent out, well above the 52-week tightest point of 257%. Cost to borrow has actually eased, falling more than 23% on the week to just 0.42%, a low-single-digit figure that signals no squeeze pressure. The ORTEX short score has drifted higher to 55.8, its highest reading of the past two weeks, but the borrow market itself remains loose. This is a deliberate bearish bet, not a forced one.

Options positioning tells a mildly cautious but not alarmed story. The put/call ratio is 0.35, modestly above its 20-day average of 0.33 and half a standard deviation from the mean. That is a long way from the 52-week high of 1.41, and it suggests options traders are not yet loading up on downside protection despite the growing short base. The stock rallied 8.2% on the week to $37.13, a move that runs counter to the short build and likely reflects some short-term momentum buyers positioning ahead of results, a dynamic that puts shorts in an uncomfortable spot if the Q3 beat repeats last quarter's pattern.

The Street backdrop is broadly constructive but carries some internal tension. UBS raised its target to $48 from $36 on October 16, maintaining its Buy, and that is the most aggressive target currently on the tape relative to the $36.70 consensus mean. Barclays also lifted its target to $40 earlier in the month, keeping an Overweight. Most recent moves over the past two months have been upgrades or target raises, with only Wells Fargo holding at Equal-Weight with a $32 target. Bulls point to the Q2 print, which showed revenue of $312.4 million, subscription revenue up 14% year on year, and AI revenue up 78% to around $39 million. The $100 million TCV deal and an ARR above $150 million give the bull case genuine substance. Bears flag seat-based model risk from AI-driven automation, long 4-to-6 month sales cycles, and competitive pressure from NICE, Cisco, and potential Microsoft or Salesforce moves. With the stock trading at $37.13 against a consensus mean target of $36.70, even the bulls are not yet pricing in much of the upgrade cycle, which adds to the interest around the November 5 print.

One footnote worth carrying: Pictet Asset Management filed a Schedule 13D/A in February showing its stake had fallen from 7.4% to 3.8%. Activist filings are event-driven disclosures around the 5% threshold and holders dropping below that level may exit without further notice, so Pictet's current position is unknown. BlackRock, by contrast, disclosed a stake of 15.5% in its August 13G/A, up from 7.8%, making it the dominant passive owner on the register. Columbia Management added around 2 million shares in the quarter ending September 30, a meaningful incremental commitment at current prices.

One additional signal worth noting: the ORTEX retail attention indicator, based on Wikipedia page views and ORTEX stock-page visits, registered a z-score of 4.95 as of October 19, a sharp spike relative to the prior 90 days. That level of retail attention, arriving in the days before a known catalyst, tends to amplify both the volume and the volatility of the move when the print lands.

The setup for November 5 is therefore defined by a direct collision: short interest at a monthly high, a ample borrow market suggesting the shorts have room to add further, a Street that has been consistently raising targets but has not yet repriced much above current levels, and a stock that rallied 8% this week into the teeth of the build. What matters most next is whether Q3 AI revenue and enterprise wins sustain the trajectory that drove last quarter's 14.8% single-day gain, and whether the short base, now 11 million shares deep, covers or adds on the reaction.